Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
31 search results for:

WCLC 2019 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-09-2019 | Lung cancer | Video | Article

    Expert highlights from WCLC 2019

    WATCH  |   Advisory Board member Ross Camidge shares his top picks of the presentations at the 2019 World Conference on Lung Cancer, including the CASPIAN trial and the updated AMG 510 data (1:51).

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  2. 15-04-2019 | WCLC 2019 | Channel

    WCLC 2019

    Conference and clinical trial news coverage from the IASLC World Conference on Lung Cancer 2019 (WCLC 2019).  

  3. 04-02-2021 | Mesothelioma | News | Article
    WCLC 2020

    Real-world data support carboplatin use in malignant pleural mesothelioma

    The retrospective observational study included data from the Flatiron Health database for 787 patients with untreated MPM who were given carboplatin (n=464) or cisplatin (n=323) combination chemotherapy, with treatment initiated between 2013 and 2019.

    Author:
    Hannah Kitt
    Published in:
    IASLC 2020 World Conference on Lung Cancer; 28–31 January 2021

  4. CASPIAN study

    Further data, presented at ESMO 2019, demonstrated that the combination is associated with better patient-reported outcomes than chemotherapy alone .

  5. National Lung Matrix Trial (NLMT)

    WCLC 2019: The National Lung Matrix Trial is a series of parallel phase 2 trials testing an experimental targeted therapy in a population stratified

  6. International Lung Screen Trial (ILST)

    WCLC 2019: Background to the International Lung Screen Trial investigates whether accurate risk prediction models are superior for identifying

  7. LIBRETTO-001 trial

    Updated data presented at the World Conference on Lung Cancer 2019 demonstrated that selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced NSCLC harboring RET fusions .

  8. MYSTIC trial

    Results One analysis, focusing on patients with high tumor mutational burden was presented at the World Conference on Lung Cancer 2019.

  9. BioMILD study

    WCLC 2019: Latest results and updates on the BioMILD study examining the efficacy of plasma microRNA profiling for detection of lung cancer in heavy

  10. VIOLET study

    WCLC 2019: VIOLET study compares the effectiveness of video-assisted thoracoscopic lobectomy and open lobectomy for treating early stage lung cancer.

  11. 13-09-2019 | Non-small-cell lung cancer | News | Article

    IMpower131: Strongly PD-L1-positive NSCLC patients may benefit from atezolizumab–chemotherapy

    By Lynda Williams medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

  12. AMG 510 in NSCLC

    Presenting author Ramaswamy Govindan outlines the key findings of the non-small-cell lung cancer cohort of the trial and the next steps for the research (5:34): Govidan video Advisory Board member Ross Camidge discusses the implications of this trial in his round-up of key data presented at WCLC 2019: Camidge video

  13. RESILIENT trial

    WCLC 2019: Latest efficacy and safety results from the RESILIENT trial investigating liposomal irinotecan in patients with small-cell lung cancer.

  14. 18-09-2019 | Non-small-cell lung cancer | News | Article
    News in brief

    Nivolumab confers NSCLC survival advantage over 5 years

    The findings were presented at the IASLC World Conference on Lung Cancer 2019 in Barcelona, Spain.

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  15. 12-09-2019 | Non-small-cell lung cancer | News | Article

    LIBRETTO-001: Selpercatinib achieves high ORRs in RET fusion-positive NSCLC

    Selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced non-small-cell lung cancer harboring RET fusions, show updated trial data presented at the IASLC World Conference on Lung Cancer 2019.

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  16. 16-09-2019 | Non-small-cell lung cancer | News | Article

    Special NSCLC populations can benefit from nivolumab plus ipilimumab

    By Laura Cowen medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  17. 12-09-2019 | Screening | News | Article

    microRNA plus LDCT guides optimal lung cancer screening intensity

    By Laura Cowen medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  18. 11-09-2019 | Lung cancer | News | Article

    VATS in-hospital outcomes may better those of open lobectomy

    By Laura Cowen medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  19. 10-09-2019 | Non-small-cell lung cancer | News | Article
    News in brief

    Durable pembrolizumab survival benefit seen in KEYNOTE-024

    These results were presented at the IASLC World Conference on Lung Cancer 2019 in Barcelona, Spain.

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September
  20. 09-09-2019 | Non-small-cell lung cancer | News | Article

    TMB does not predict NSCLC pembrolizumab–chemotherapy response

    By Lynda Williams medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

    Published in:
    IASLC World Conference on Lung Cancer 2019; Barcelona, Spain: 7–10 September

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.